A novel effervescent formulation of oral weekly alendronate (70 mg) improves persistence compared to alendronate tablets in post-menopausal women with osteoporosis
Sign Up to like & getrecommendations! Published in 2021 at "Aging Clinical and Experimental Research"
DOI: 10.1007/s40520-020-01777-9
Abstract: Background A novel effervescent buffered solution of 70 mg alendronate (ALN-EX) was developed to improve upper gastrointestinal (GI) tolerability over alendronate tablets (ALN-T). Whether a better GI tolerability can improve persistence remains to be determined. Aim… read more here.
Keywords: menopausal women; post menopausal; novel effervescent; aln ... See more keywords